Advertisement

Alvimopan reduces length of stay and costs in patients undergoing segmental colonic resections: results from multicenter national administrative database

Published:September 20, 2014DOI:https://doi.org/10.1016/j.amjsurg.2014.08.011

      Abstract

      Background

      Alvimopan (Entereg), a peripherally acting mu-opioid receptor antagonist, has been shown to expedite recovery of bowel function after colon resection surgery. Most data are available from industry-sponsored trials. This study aims to evaluate the clinical impact of this drug on perioperative outcomes and costs in patients undergoing segmental colonic resection for diverticular disease.

      Methods

      A large administrative database maintained by the University Health System Consortium, an alliance of over 200 academic and affiliate hospitals, was queried from 2008 to 2011. International Classification of Diseases, 9th Revision, Clinical Modification codes for segmental colon resection because of diverticular disease were used to identify 2 matched cohorts of adult patients. University Health System Consortium's clinical resource manager was used to access pharmacy data and compare it with patient outcomes.

      Results

      Five thousand two hundred ninety-nine patients met the above criteria. Four hundred thirty-eight patients received alvimopan and 4,861 did not. Regardless of laparoscopic or open approach, alvimopan significantly improved the postoperative length of stay (4.43 ± 2.02 vs 5.92 ± 3.79, P < .0001), cost (9,974 ± 4,077 vs 11,303 ± 6,968, P < .0001), and intensive care unit admission rate (1.83% vs 7.20%, P < .05), with no significant difference in mortality (.0% vs .19%, P = 1.000), morbidity (5.93% vs 8.39%, P = .08), or 30-day readmission rate (4.40% vs 4.63%, P = .90).

      Conclusions

      Alvimopan significantly reduced length of stay, days in the intensive care unit, and hospital cost for patients undergoing colonic segmental resections. Unlike some previously reported studies, we also observed a significant reduction in the length of stay in patients undergoing laparoscopic colectomies who received the drug. Alvimopan may reduce total healthcare costs if used as part of a best care practice model for colon resections.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Healthcare Costs and Utilization Project (HCUP). 2002 National Statistics. Available at: http://www.ahrq.gov/HCUPnet. Accessed March 20, 2014.

        • Iyer S.
        • Saunders W.B.
        • Stemkowski S.
        Economic burden of postoperative ileus associated with colectomy in the United States.
        J Manag Care Pharm. 2009; 15: 485-494
        • Augestad K.M.
        • Delaney C.P.
        Postoperative ileus: impact of pharmacological treatment, laparoscopic surgery and enhanced recovery pathways.
        World J Gastroenterol. 2010; 16: 2067-2074
        • Baumgartner R.G.
        • Wells N.
        • Chang S.S.
        • et al.
        Causes of increased hospital stay after radical cystectomy in a clinical pathway setting.
        J Urol. 2002; 167: 208-211
        • Kurz A.
        • Sessler D.I.
        Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
        Drugs. 2003; 63: 649-671
        • Luckey A.
        • Livingston E.
        • Taché Y.
        Mechanisms and treatment of postoperative ileus.
        Arch Surg. 2003; 138: 206-214
        • Holte K.
        • Kehlet H.
        Postoperative ileus: progress towards effective management.
        Drugs. 2002; 62: 2603-2615
        • Holte K.
        • Kehlet H.
        Postoperative ileus: a preventable event.
        Br J Surg. 2000; 87: 1480-1493
        • Austrup M.L.
        • Korean G.
        Analgesic agents for the postoperative period. Opioids.
        Surg Clin North Am. 1999; 79: 253-273
        • Delaney C.P.
        • Craver C.
        • Gibbons M.M.
        • et al.
        Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection.
        Ann Surg. 2012; 255: 731-738
        • Lee C.T.
        • Chang S.S.
        • Kamat A.M.
        • et al.
        Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.
        Eur Urol. 2014; 66: 265-272
        • Keller D.
        • Stein S.L.
        Facilitating return of bowel function after colorectal surgery: alvimopan and gum chewing.
        Clin Colon Rectal Surg. 2013; 26: 186-190
        • Delaney C.P.
        • Wolff B.G.
        • Viscusi E.R.
        • et al.
        Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies.
        Ann Surg. 2007; 245: 355-363
      2. Available at: www.uhc.edu. Accessed March 20, 2014.

        • Nguyen N.T.
        • Hinojosa M.
        • Fayad C.
        • et al.
        Use and outcomes of laparoscopic versus open gastric bypass at academic medical centers.
        J Am Coll Surg. 2007; 205: 248-255
        • Hinojosa M.W.
        • Murrell Z.A.
        • Konyalian V.R.
        • et al.
        Comparison of laparoscopic vs. open sigmoid colectomy for benign and malignant disease at academic medical centers.
        J Gastrointest Surg. 2007; 11 (discussion, 1429–0): 1423-1429
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • et al.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Viscusi E.R.
        • Goldstein S.
        • Witkowski T.
        • et al.
        Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study.
        Surg Endosc. 2006; 20: 64-70
        • Ludwig K.
        • Enker W.E.
        • Delaney C.P.
        • et al.
        Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.
        Arch Surg. 2008; 143: 1098-1105
        • Delaney C.P.
        • Weese J.L.
        • Hyman N.H.
        • et al.
        • Alvimopan Postoperative Ileus Study Group
        Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.
        Dis Colon Rectum. 2005; 48 (discussion, 1125–6. Author reply 1127–1129): 1114-1125
        • Büchler M.W.
        • Seiler C.M.
        • Monson J.R.
        • et al.
        Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study.
        Aliment Pharmacol Ther. 2008; 28: 312-325
        • Wolff B.G.
        • Michelassi F.
        • Gerkin T.M.
        • et al.
        • Alvimopan Postoperative Ileus Study Group
        Alvimopan, a novel, peripherally acting μ opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.
        Ann Surg. 2004; 240: 728-735
        • Bell T.J.
        • Poston S.A.
        • Kraft M.D.
        • et al.
        Economic analysis of alvimopan in North American Phase III efficacy trials.
        Am J Health Syst Pharm. 2009; 66: 1362-1368
        • Kelley S.R.
        • Wolff B.G.
        • Lovely J.K.
        • et al.
        Fast-track pathway for minimally invasive colorectal surgery with and without alvimopan (Entereg)™: which is more cost-effective?.
        Am Surg. 2013; 79: 630-633
        • Hilton W.M.
        • Lotan Y.
        • Parekh D.J.
        • et al.
        Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis.
        BJU Int. 2013; 111: 1054-1060